SkinnyRx Tirzepatide Review 2026: Tablets vs Injection

Review SkinnyRx’s Injectable Tirzepatide Pathway

Review SkinnyRx’s Tirzepatide Tablet Pathway

Affiliate disclosure: Care Path Compare may receive compensation if you use a SkinnyRx link and make a purchase, at no extra cost to you. Compensation does not determine our editorial conclusions. Eligibility, prescribing, formulation, pharmacy fulfillment, and final price remain subject to clinician review and current provider terms.

SkinnyRx tirzepatide at a glance

Question	Current public information	What to verify before paying
Tirzepatide formats	Compounded daily tablet and compounded weekly injection	Exact formulation and route prescribed for you
Advertised starting price	From $299/month for each current compounded pathway	Today’s charge, renewal price, dose-related changes, and any promotional conditions
FDA approval	SkinnyRx labels both pathways as compounded; compounded drugs are not FDA-approved	Do not treat either as an FDA-approved generic or equivalent product
Clinician review	SkinnyRx says a licensed provider reviews the medical intake	Intake completion does not guarantee a prescription or a specific product
Pharmacy	SkinnyRx describes fulfillment through licensed U.S. or partner pharmacies	Legal dispensing-pharmacy name, location, license, formulation, and concentration
Follow-up	Patient portal, refill check-ins, and clinician questions are described	Response times and whether any additional visits or testing apply
Cancellation	Future subscription months may be canceled before the next shipment is prepared	Exact cutoff for the next charge and shipment
Refund cutoff	SkinnyRx says full refund is available before prescription review is completed; fulfillment makes the order nonrefundable	Save the checkout terms and cancellation confirmation
Regulatory history	FDA issued Lean Rx, Inc. dba SkinnyRx a warning letter on February 20, 2026	Current corrective status and any later FDA correspondence

Information and prices were checked August 8, 2026 and can change.

What tirzepatide products does SkinnyRx currently advertise?

SkinnyRx’s current weight-care page presents two compounded tirzepatide options side by side:

Compounded tirzepatide tablets: once daily, advertised from $299 per month.
Compounded injectable tirzepatide: once weekly, advertised from $299 per month.

SkinnyRx also offers separate branded-medication pathways elsewhere on its site. Those should not be blended together with the compounded options. A consumer comparing SkinnyRx tirzepatide should identify the exact product being discussed at every step: compounded tablet, compounded injection, or an FDA-approved branded injection.

SkinnyRx tirzepatide tablets vs injection

The two SkinnyRx pathways differ in more than dosing frequency.

Feature	Compounded tirzepatide tablet	Compounded tirzepatide injection
Current SkinnyRx presentation	Daily tablet	Weekly injection
Advertised starting price	From $299/month	From $299/month
Regulatory status	Compounded; not FDA-approved	Compounded; not FDA-approved
Administration	SkinnyRx’s patient instructions describe a tablet placed between the gum and cheek to dissolve	SkinnyRx’s patient instructions describe a subcutaneous injection
Food/timing instructions	SkinnyRx gives specific morning and food/beverage timing instructions	SkinnyRx says no special food or drink restriction is needed around the weekly injection
Evidence question	Do not transfer evidence from FDA-approved injectable tirzepatide automatically to this compounded tablet	Do not assume a compounded injection is identical to an FDA-approved branded injection
Key verification	Exact tablet formulation, strength, pharmacy, administration instructions, and evidence basis	Exact concentration, dose, supplies, pharmacy, storage, and administration instructions

The practical takeaway is that “tirzepatide” does not make the two pathways interchangeable. Route, formulation, concentration, absorption, dosing instructions, pharmacy preparation, and regulatory status all matter.

The tablet is not an FDA-approved oral tirzepatide product

SkinnyRx’s patient-facing instructions describe its compounded tablet as a daily product that dissolves between the gum and cheek and includes timing restrictions around food, beverages, and other oral medications.

That matters because FDA-approved tirzepatide products such as Zepbound and Mounjaro are labeled as subcutaneous injections. Their approved labeling and clinical evidence should not be presented as proof that a separately compounded tablet has the same absorption, effectiveness, safety profile, or dosing behavior.

A useful question for the prescribing clinician is:

What evidence supports the exact compounded tirzepatide formulation and route being prescribed to me?

The compounded injection is not an FDA-approved generic

A compounded tirzepatide injection may look more similar in route to an approved tirzepatide injection, but it is still a compounded drug. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality, and FDA specifically warns against describing compounded products as generic, equivalent, or the same as approved medications.

Consumers should therefore confirm the actual dispensing pharmacy, concentration, formulation, storage instructions, supplies, and prescription-specific directions rather than assuming the product is interchangeable with Zepbound or Mounjaro.

How much does SkinnyRx tirzepatide cost?

As of August 8, SkinnyRx’s main weight-care page advertises both its compounded tirzepatide tablet and injectable pathways from $299 per month.

The phrase “from” matters. A starting price does not establish every consumer’s final recurring cost.

Before paying, confirm in writing:

The amount charged today.
Whether $299 requires a promotion, bundle, or committed term.
The standard renewal amount.
Whether price changes with prescribed dose or formulation.
How many doses or shipments each charge covers.
Whether shipping and supplies are included.
The next billing and shipment date.
The financial effect of canceling a promotion or bundled plan early.

For broader pricing context, see our SkinnyRx cost guide.

How SkinnyRx says the prescription process works

SkinnyRx currently describes a four-step process: complete an online assessment, receive licensed-clinician review, receive medication if prescribed, and continue with care-team support and tracking tools.

Its FAQ says state-specific requirements may affect whether a video visit is needed. It also describes refill forms and ongoing access to the patient care team and clinicians.

Completing the questionnaire or choosing a tirzepatide product does not guarantee eligibility, a prescription, a particular formulation, a particular dose, or continued refills. Those decisions belong to the licensed clinician, and fulfillment depends on the prescription and pharmacy.

What pharmacy fills SkinnyRx tirzepatide?

SkinnyRx says prescription products can be filled through partner pharmacies and describes its GLP-1 products as coming from licensed U.S. pharmacies. However, the public information we reviewed does not identify one dispensing pharmacy that will necessarily fill every SkinnyRx tirzepatide prescription.

That is an important transparency question for compounded medication.

Before fulfillment, ask for:

The pharmacy’s full legal name.
Its physical location.
The state license under which it will dispense to you.
Whether it is operating as a 503A pharmacy or under another applicable model.
The exact prescribed formulation and concentration.
Storage and shipping instructions.
Who to contact for a pharmacy or dispensing problem.

FDA recommends that patients obtain compounded medications only with a prescription and through a properly licensed pharmacy. FDA also notes that consumers using telehealth platforms may not always know which compounder actually produced the medication.

What changed after the tirzepatide shortage ended?

This is one of the most important pieces of current context.

FDA determined that the tirzepatide injection shortage was resolved in December 2024. In April 2026, FDA reiterated that tirzepatide was not on its drug-shortage list and reminded compounders that 503A and 503B exemptions contain restrictions on making products that are essentially copies of commercially available approved drugs.

That does not mean every patient-specific compounded tirzepatide prescription is automatically unlawful. Section 503A can permit patient-specific compounding when statutory conditions are satisfied, and the specific facts of the prescription and pharmacy matter.

For consumers, the useful question is not “Is all compounded tirzepatide banned?” It is:

What patient-specific medical need and compounding framework apply to this prescription now that tirzepatide is not on FDA’s shortage list?

Care Path Compare does not make a legal or medical determination about an individual prescription. Ask the prescribing clinician and dispensing pharmacy to explain the basis that applies to the specific compounded product.

What did FDA say about SkinnyRx in 2026?

FDA issued Lean Rx, Inc. dba SkinnyRx a warning letter dated February 20, 2026 after reviewing SkinnyRx’s website in December 2025.

FDA said the site used false or misleading representations involving compounded semaglutide and tirzepatide. The letter specifically objected to product-label presentation that suggested SkinnyRx itself was the compounder when FDA said it was not, and to claims implying compounded products had the same active ingredient or FDA-reviewed status as approved medications.

FDA requested corrective action and a written response.

SkinnyRx’s current home page is clearer in several important respects: it explicitly labels the tirzepatide tablet and injection as compounded and states that compounded drugs are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality.

We did not locate an FDA close-out letter confirming formal resolution of the February warning as of August 8, 2026. That does not establish that SkinnyRx failed to make corrections. It means consumers should distinguish the documented historical warning from claims about present compliance and should not assume formal FDA closure without a source.

Does SkinnyRx tirzepatide work?

This question appears prominently in current search results, but a responsible answer has to separate products.

FDA-approved tirzepatide injections have approved labeling and clinical-trial evidence for their respective indications. SkinnyRx’s compounded tablet is a different formulation and route, so that evidence cannot simply be transferred to it. SkinnyRx’s compounded injection is also not FDA-approved and should not be represented as clinically equivalent to an approved branded injection.

Individual outcomes also vary, and a telehealth provider, payment, or prescription cannot guarantee weight loss or another health result.

Rather than relying on a generalized claim that “tirzepatide works,” ask the clinician what evidence is relevant to the exact product, formulation, route, dose, and medical purpose being considered.

SkinnyRx cancellation and refund terms

SkinnyRx’s current FAQ describes two separate concepts that consumers should not confuse:

Refund cutoff: SkinnyRx says an order may receive a full refund before a licensed provider completes prescription review. Once review is completed and fulfillment begins, the order becomes nonrefundable.
Future cancellation: Ongoing subscription months may be canceled before the next shipment is prepared.

SkinnyRx also says promotional or committed-term discounts may be reversed or proportionally adjusted after early cancellation, and that partially used subscription periods and bundled subscriptions are generally nonrefundable.

So “cancel future months” does not necessarily mean “refund a medication order already reviewed or in fulfillment.”

Save the checkout page, next renewal date, cancellation request, and written confirmation. Our GLP-1 cancellation and refund guide explains the broader questions to ask before joining a recurring program.

Questions to ask before choosing a SkinnyRx tirzepatide pathway

For either the tablet or injection, ask:

What exact product is being prescribed? Get the formulation, route, strength, and concentration in writing.
Why is a compounded product appropriate for my individual situation? Ask what patient-specific need applies.
Which pharmacy will dispense it? Get the pharmacy’s legal name, location, and license.
What evidence applies to this exact formulation? This is especially important for the compounded tablet.
What will I pay now and at renewal? Do not rely only on the $299 starting figure.
Does price change with dose? Ask before the first renewal.
What supplies and shipping are included? Particularly for injectable medication.
What is the refund cutoff? Determine when clinician review or fulfillment makes the order nonrefundable.
What happens if the clinician does not prescribe it? Confirm the written refund process.
What follow-up is included? Ask about refill reviews, questions, side effects, and any required testing.
Is treatment available in my state? Affiliate availability is not the same as clinical availability.
What should I do if the pharmacy, packaging, concentration, or instructions differ from what I expected? Know who is responsible before shipment.

Use our online provider-verification checklist for a broader due-diligence process.

Bottom line

SkinnyRx’s tirzepatide offering is worth comparing because the company currently provides clear entry points for both a compounded tablet and compounded injection, advertises the same $299-per-month starting price for each, and places prescribing decisions with licensed clinicians.

The tradeoff is that the comparison requires more scrutiny than a simple price-and-format choice. Both SkinnyRx options are compounded and not FDA-approved; the tablet is a distinct formulation that should not inherit evidence from FDA-approved injections; the actual dispensing pharmacy is not identified universally on the public pages we reviewed; and SkinnyRx has relevant FDA warning-letter history from February 2026.

A sensible comparison therefore focuses on the exact prescription, pharmacy, formulation, total recurring cost, administration instructions, and patient-specific reason for compounding rather than assuming that every product labeled tirzepatide is the same.